Evidence map›Paper›PMID 30205039›Full record

ArticleCancer cell2018

Multiomic Medulloblastomas.

Eric P Rahmann, Richard J Gilbertson

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Medulloblastoma: biology and immunotherapy.Frontiers in immunology · 2025
    Review
  2. Article
  3. Review
  4. A systematic view of pediatric medulloblastoma proteomics-current state of the field and future directions.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021
    Review
  5. Premetastasis.Cold Spring Harbor perspectives in medicine · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Eric P RahmannCRUK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
Richard J GilbertsonCRUK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK; Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge CB2 0XZ, UK. Electronic address: richard.gilbertson@cruk.cam.ac.uk.

Funding

The DNA Damage Response and Tumorigenesis in the BrainP01CA096832 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SUZANNE J. · 2003 to 2025
$38.0M
Cancer Research UK 22492NCI NIH HHS P01 CA096832
6 · The paper itself

Abstract

Epigenomics and transcriptomics of medulloblastoma-an important childhood brain tumor-segregate the disease into four clinically relevant subtypes. In this issue of Cancer Cell, Archer et al. and Forget et al. add the proteome to our multiomic map of this disease, revealing posttranscriptional and posttranslational variations with potential therapeutic implications.

Indexed as

Brain NeoplasmsCerebellar NeoplasmsMedulloblastomaChildHumansReceptor, ErbB-4Signal TransductionERBB4 protein, humanReceptor, ErbB-4

Identifiers

PMID30205039

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.